V
31.20
3.16 (11.27%)
| Penutupan Terdahulu | 28.04 |
| Buka | 27.97 |
| Jumlah Dagangan | 4,046,888 |
| Purata Dagangan (3B) | 1,901,488 |
| Modal Pasaran | 4,017,374,464 |
| Harga / Buku (P/B) | 1.25 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| EPS Cair (TTM) | -3.80 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.15% |
| Nisbah Semasa (MRQ) | 12.76 |
| Aliran Tunai Operasi (OCF TTM) | -452.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -403.44 M |
| Pulangan Atas Aset (ROA TTM) | -14.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.41% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Vaxcyte, Inc. | Menurun | Menaik |
AISkor Stockmoo
2.0
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 2.00 |
|
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.50% |
| % Dimiliki oleh Institusi | 111.97% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 160.00 (Guggenheim, 412.82%) | Beli |
| Median | 118.50 (279.81%) | |
| Rendah | 90.00 (Needham, 188.46%) | Beli |
| Purata | 121.75 (290.22%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 41.98 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 08 Apr 2025 | 90.00 (188.46%) | Beli | 30.20 |
| 01 Apr 2025 | 90.00 (188.46%) | Beli | 32.23 | |
| B of A Securities | 01 Apr 2025 | 137.00 (339.10%) | Beli | 32.23 |
| Goldman Sachs | 01 Apr 2025 | 100.00 (220.51%) | Beli | 32.23 |
| Guggenheim | 12 Mar 2025 | 160.00 (412.82%) | Beli | 73.24 |
| 26 Feb 2025 | 160.00 (412.82%) | Beli | 78.65 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 31 Mar 2025 | Pengumuman | Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study |
| 30 Mar 2025 | Pengumuman | Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study |
| 25 Feb 2025 | Pengumuman | Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 12 Feb 2025 | Pengumuman | Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 |
| 05 Feb 2025 | Pengumuman | Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants |
| 30 Jan 2025 | Pengumuman | Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |